|
Daily Medical Update
Inherited cancer risk
Friday, May 22, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Journal of the National Cancer Institute (2026) - Systematic Review and Meta-analysis
Key Findings
- At age 40, colorectal cancer risk was less than 2% in MSH6 and PMS2 carriers versus more than 4% in MLH1 and MSH2 carriers.
- At age 50, endometrial cancer risk was 8.3% for MLH1, 8.7% for MSH2, 5.2% for MSH6, and 3.0% for PMS2; ovarian cancer risk at age 40 was 1.2% for MLH1 and 0.9% for MSH2.
📋 Practice Implication: Use the specific Lynch gene, rather than the syndrome label alone, to set timing for colonoscopy and discussions about hysterectomy or oophorectomy.
|
Maturitas (2026) - Meta-analysis
Key Findings
- Estimated prevalence in female Lynch syndrome carriers was 20% for endometrial cancer, 5.7% for ovarian cancer, and 11% for breast cancer.
- MSH6 increased endometrial cancer risk (OR 1.46, 95% CrI 1.02-2.04), while PMS2 reduced it (OR 0.36, 95% CrI 0.14-0.95); breast cancer risk increased with PMS2 (OR 1.52) and MSH6 (OR 2.27).
📋 Practice Implication: For women with Lynch syndrome, gynecologic counseling should be gene-specific, with closer attention to MSH6 and PMS2 when discussing endometrial risk and the still-uncertain breast cancer signal.
|
Annals of Surgical Oncology (2025) - Systematic Review and Meta-analysis
Key Findings
- In 29,170 patients with Lynch syndrome, male sex (RR 2.8), MLH1 (RR 1.8), MSH2 (RR 2.5), family history of gastric cancer (RR 3.5), and Helicobacter pylori infection (RR 2.8) increased gastric cancer risk.
- MSH6 was associated with reduced gastric cancer risk (RR 0.6, 95% CI 0.4-0.8) compared with other mismatch repair variants.
📋 Practice Implication: Reserve the strongest upper GI surveillance focus for Lynch patients with MLH1 or MSH2 variants, male sex, gastric cancer family history, or H. pylori exposure, and treat H. pylori as a modifiable risk target.
|
The Australasian Journal of Dermatology (2025) - Meta-analysis
Key Findings
- Across 9 studies, Lynch syndrome prevalence in sebaceous neoplasms ranged from 0.8% to 29.0%, and pooled prevalence in sebaceous carcinomas was 6.6% (95% CI 3.6%-9.5%).
- Population-based cohorts showed a 10.6% Lynch syndrome identification rate, and MMR-deficient or Muir-Torre-suggestive tumors showed increased Lynch syndrome prevalence versus unselected cases.
📋 Practice Implication: Treat sebaceous neoplasms as a practical trigger for Lynch evaluation, especially when tumors are MMR-deficient or the clinical history suggests Muir-Torre syndrome.
|
Urologic Oncology (2026) - Systematic Review and Meta-analysis
Key Findings
- Across 14 studies and 2,378 patients with upper tract urothelial carcinoma, pooled prevalence of germline mismatch repair mutations was 3.2% (95% CI 2.1%-4.4%; I2=54%).
- Prevalence was 2.4% in East Asian studies versus 4.7% in North American and European studies, and 86% of mutation-positive patients were younger than 60 years or had a prior cancer diagnosis.
📋 Practice Implication: Upper tract urothelial carcinoma should prompt Lynch testing consideration, particularly in patients diagnosed before age 60 or with a personal history of another Lynch-associated cancer.
|
|
💡
Summary
Recent evidence on inherited cancer risk was dominated by Lynch syndrome meta-analyses, with newer data supporting gene-specific rather than syndrome-wide surveillance decisions. Risk estimates varied materially by mismatch repair gene, sex, extracolonic site, and sentinel presentations such as sebaceous neoplasms or upper tract urothelial carcinoma. These studies support more targeted testing and counseling pathways instead of treating all hereditary cancer syndromes as uniform high-risk groups.
|
|